June 8, 2018 –

Abstract

Highlights

FUS conveys an ultrasound beam at target points at certain frequencies.

The objective of the research was to apply FUS to the treatment of intracranial neoplastic diseases.

We review the latest studies to take stock of the potential of FUS.

New mini invasive therapies may become main players in the treatment of brain neoplasms, aided by FUS.

Background

Despite the progress achieved in recent years, the prognosis of patients with primary brain tumors remains poor. Research efforts have therefore focused on identifying more effective and minimally invasive treatment methods. Magnetic resonance–guided transcranial focused ultrasonography (MRgFUS) is a consolidated minimally invasive therapeutic technique, which has recently acquired a role also in the treatment of some nononcologic intracranial diseases.

Methods

We reviewed the latest studies to take stock of the potential of MRgFUS.

Results

The objective of the research in the last decade was to apply FUS also to the treatment of intracranial neoplastic diseases, using both the thermal effects (thermal ablation) and, above all, the ability to permeabilize the blood-brain barrier and modify the tumor microenvironment. This strategy may allow the use of drugs that are poorly active on the central nervous system or active selectively at high doses, minimize the side effects, and substantially modify the prognosis of patients affected by these diseases.

Conclusions

In the future, targeted drug delivery, immunotherapy, and gene therapy will probably become main players in the treatment of brain neoplasms, with the aid of MRgFUS. In this way, it will be possible to directly intervene on tumor cells and preserve healthy tissue.

World Neurosurgery, Vol. 117, p84–91

DOI: https://doi.org/10.1016/j.wneu.2018.05.239

Authors: Giada Toccaceli1,5, Roberto Delfini2, Claudio Colonnese3,4, Antonino Raco1, Simone Peschillo5

1NESMOS Departmente Division of Neurosurgery, 2 Department of Human Neurosciences, Neurosurgery, and 3 Department of Human Neurosciences, Neuroradiology, University of Rome, “Sapienza”, Rome; 4 IRCCS INMNeuromed, Pozzilli, Italy; and 5Endovascular Neurosurgery, Policlinico Umberto I, Rome, Italy

To whom correspondence should be addressed: Simone Peschillo, M.D., Ph.D.